Emerging Roles of SIRT5 in Metabolism, Cancer, and SARS-CoV-2 Infection

Cells. 2023 Mar 9;12(6):852. doi: 10.3390/cells12060852.

Abstract

Sirtuin 5 (SIRT5) is a predominantly mitochondrial enzyme catalyzing the removal of glutaryl, succinyl, malonyl, and acetyl groups from lysine residues through a NAD+-dependent deacylase mechanism. SIRT5 is an important regulator of cellular homeostasis and modulates the activity of proteins involved in different metabolic pathways such as glycolysis, tricarboxylic acid (TCA) cycle, fatty acid oxidation, electron transport chain, generation of ketone bodies, nitrogenous waste management, and reactive oxygen species (ROS) detoxification. SIRT5 controls a wide range of aspects of myocardial energy metabolism and plays critical roles in heart physiology and stress responses. Moreover, SIRT5 has a protective function in the context of neurodegenerative diseases, while it acts as a context-dependent tumor promoter or suppressor. In addition, current research has demonstrated that SIRT5 is implicated in the SARS-CoV-2 infection, although opposing conclusions have been drawn in different studies. Here, we review the current knowledge on SIRT5 molecular actions under both healthy and diseased settings, as well as its functional effects on metabolic targets. Finally, we revise the potential of SIRT5 as a therapeutic target and provide an overview of the currently reported SIRT5 modulators, which include both activators and inhibitors.

Keywords: HDACs; SIRT5; SIRT5 modulators; epigenetic; protein lysine desuccinylation; sirtuins.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19* / metabolism
  • Humans
  • Metabolic Networks and Pathways
  • Neoplasms* / metabolism
  • SARS-CoV-2 / metabolism
  • Sirtuins* / metabolism

Substances

  • SIRT5 protein, human
  • Sirtuins

Grants and funding

This work was supported by Italian Ministry of University FISR2019_00374 MeDyCa (A.M.), “Sapienza” Ateneo Project 2021 n. RM12117A61C811CE (D.R.), Regione Lazio PROGETTI DI GRUPPI DI RICERCA 2020-A0375-2020-36597 (D.R.). F.F. is supported by the E.U.’s Horizon Europe program under the Marie Skłodowska-Curie grant agreement EpiPolyPharma 101062363.